Tag: Arkon Solution

Kineret, a biologic drug, can prevent gout flare-ups

Kineret, a biologic drug, can prevent gout flare-ups

Gout is a prevalent type of auto-inflammatory arthritis that develops when MSU crystals accumulate in the synovial joints’ soft tissue. Acute gout flare-ups are marked by specific inflammatory symptoms such as pain, erythema, and edoema. They can lead to physical incapacity and a lowered quality of life. Therefore, one of the key objectives in treating […]
Read More
In older or less-fit CLL patients, first-line ibrutinib plus venetoclax improves outcomes

In older or less-fit CLL patients, first-line ibrutinib plus venetoclax improves outcomes

In older or less-fit CLL patients, first-line ibrutinib plus venetoclax improves outcomes Ibrutinib, an oral BTK inhibitor taken once daily, is the only targeted treatment to show improved progression-free survival (PFS). Venetoclax is a single agent or combination with rituximab or obinutuzumab for treating CLL and SLL. It is an oral inhibitor of the anti-apoptotic […]
Read More
The evolving role of Brentuximab Vedotin in classical Hodgkin Lymphoma

The evolving role of Brentuximab Vedotin in classical Hodgkin Lymphoma

With the introduction of Brentuximab Vedotin, a CD30-directed antibody-drug combination, the treatment strategy for people with classical Hodgkin lymphoma has changed. Since its first approval in 2011, BV has been thoroughly investigated in patients who had not previously received any treatment, relapsed, or were treated unsuccessfully. The antibody-drug conjugate’s indications for use in patients have […]
Read More
High Dose Anakinra shows promise in treating CRS

High-Dose Anakinra shows promise in treating CRS/ICANS Post CAR T-Cell Therapy

The possibility of the cutting-edge therapeutic approach known as chimeric antigen receptor (CAR) T-cell immunotherapy to treat a variety of resistant haematological malignancies has attracted attention. The serious side effects of CAR T-cell treatment continue to be of great concern. Early after CAR-T cell therapy, cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome are […]
Read More